The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 09, 2024

Filed:

Mar. 26, 2019
Applicants:

Systimmune, Inc., Redmond, WA (US);

Sichuan Baili Pharmaceutical Co. Ltd., Sichuan, CN;

Inventors:

Yi Zhu, Sichuan, CN;

Ole Olsen, Everett, WA (US);

Dong Xia, Redmond, WA (US);

David Jellyman, Duvall, WA (US);

Katrina Bykova, Seattle, WA (US);

Anne-Marie Rousseau, Seattle, WA (US);

Bill Brady, Bothell, WA (US);

Blair Renshaw, Renton, WA (US);

Brian Kovacevich, Snohomish, WA (US);

Yu Liang, Redmond, WA (US);

Camilla Wang, Sammamish, WA (US);

Zeren Gao, Redmond, WA (US);

Hui Huang, Redmond, WA (US);

Assignee:

SYSTIMMUNE, INC., Redmond, WA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 5/09 (2010.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 14/70503 (2013.01); C07K 14/7051 (2013.01); C07K 14/70532 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2878 (2013.01); C12N 5/0638 (2013.01); C12N 5/0693 (2013.01); G01N 33/57488 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the guidance and navigation control (GNC) protein, comprising a binding domain for a T cell activating receptor, a binding domain for a tumor associated antigen, a bind domain for an immune checkpoint receptor, and a binding domain for a T cell co-stimulating receptor. The binding domain for the tumor associated antigen is not adjacent to the binding domain for the T cell co-stimulating receptor. In one embodiment, the binding domain for the T cell activating receptor is adjacent to the binding domain for the tumor associated antigen (TAA).


Find Patent Forward Citations

Loading…